Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1974 2
1975 6
1976 3
1977 1
1978 2
1980 2
1981 2
1982 1
1983 1
1985 2
1989 1
1990 3
1991 4
1992 3
1993 2
1994 5
1995 5
1996 14
1997 8
1998 24
1999 13
2000 22
2001 11
2002 13
2003 8
2004 8
2005 14
2006 15
2007 11
2008 13
2009 11
2010 20
2011 21
2012 19
2013 23
2014 24
2015 24
2016 31
2017 31
2018 24
2019 36
2020 29
2021 32
2022 22
2023 43
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

582 results

Results by year

Filters applied: . Clear all
Page 1
Cerebrolysin for acute ischaemic stroke.
Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K. Ziganshina LE, et al. Cochrane Database Syst Rev. 2023 Oct 11;10(10):CD007026. doi: 10.1002/14651858.CD007026.pub7. Cochrane Database Syst Rev. 2023. PMID: 37818733 Review.
This is an update of a review first published in 2010 and last updated in 2020. OBJECTIVES: To assess the benefits and harms of Cerebrolysin or Cerebrolysin-like agents for treating acute ischaemic stroke. ...AUTHORS' CONCLUSIONS: Moderate-certainty evidence indicat …
This is an update of a review first published in 2010 and last updated in 2020. OBJECTIVES: To assess the benefits and harms of Cerebroly …
Cerebrolysin: a multi-target drug for recovery after stroke.
Brainin M. Brainin M. Expert Rev Neurother. 2018 Aug;18(8):681-687. doi: 10.1080/14737175.2018.1500459. Epub 2018 Jul 18. Expert Rev Neurother. 2018. PMID: 30004268 Review.
Cerebrolysin is a neuropeptide preparation with neurotrophic effects and promotes recovery after brain injury. ...Based on the findings from several studies, it became evident that the effect size of Cerebrolysin was increasing with stroke severity. Other controlled …
Cerebrolysin is a neuropeptide preparation with neurotrophic effects and promotes recovery after brain injury. ...Based on the findin …
Cerebrolysin for acute ischaemic stroke.
Ziganshina LE, Abakumova T, Vernay L. Ziganshina LE, et al. Cochrane Database Syst Rev. 2017 Apr 21;4(4):CD007026. doi: 10.1002/14651858.CD007026.pub5. Cochrane Database Syst Rev. 2017. PMID: 28430363 Free PMC article. Updated. Review.
BACKGROUND: Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from pigs' brain tissue, which has potential neuroprotective and neurotrophic properties. ...AUTHORS' CONCLUSIONS: The findings of this Cochrane Review do not demonstrate clinica …
BACKGROUND: Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from pigs' brain tissue, which has pot …
Cerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis.
Kojder K, Jarosz K, Bosiacki M, Andrzejewska A, Zach S, Solek-Pastuszka J, Jurczak A. Kojder K, et al. J Clin Med. 2023 Oct 20;12(20):6638. doi: 10.3390/jcm12206638. J Clin Med. 2023. PMID: 37892776 Free PMC article. Review.
Methods of treatment are investigated in order to obtain the best treatment result, not only survival. One of the drugs used in stroke, including SAH, is Cerebrolysin. It is a mixture of neuropeptides that has similar properties to neurotrophic factors. ...Therefore, we co …
Methods of treatment are investigated in order to obtain the best treatment result, not only survival. One of the drugs used in stroke, incl …
Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes.
Fiani B, Covarrubias C, Wong A, Doan T, Reardon T, Nikolaidis D, Sarno E. Fiani B, et al. Neurol Sci. 2021 Apr;42(4):1345-1353. doi: 10.1007/s10072-021-05089-2. Epub 2021 Jan 30. Neurol Sci. 2021. PMID: 33515100 Review.
Although Cerebrolysin is not approved for use in the USA, it is used clinically in over 50 countries worldwide. ...In conclusion, we found that Cerebrolysin therapy can potentially play a major role in the treatment of many neurological diseases. ...
Although Cerebrolysin is not approved for use in the USA, it is used clinically in over 50 countries worldwide. ...In conclusion, we …
Cerebrolysin for acute ischaemic stroke.
Ziganshina LE, Abakumova T, Vernay L. Ziganshina LE, et al. Cochrane Database Syst Rev. 2016 Dec 5;12(12):CD007026. doi: 10.1002/14651858.CD007026.pub4. Cochrane Database Syst Rev. 2016. PMID: 27918088 Free PMC article. Updated. Review.
BACKGROUND: Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from pigs' brain tissue, which has potential neuroprotective and neurotrophic properties. ...AUTHORS' CONCLUSIONS: The findings of this Cochrane Review do not demonstrate clinica …
BACKGROUND: Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from pigs' brain tissue, which has pot …
Cerebrolysin for vascular dementia.
Chen N, Yang M, Guo J, Zhou M, Zhu C, He L. Chen N, et al. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD008900. doi: 10.1002/14651858.CD008900.pub2. Cochrane Database Syst Rev. 2013. PMID: 23440834 Updated. Review.
BACKGROUND: Vascular dementia is a common disorder without definitive treatments. Cerebrolysin seems to be a promising intervention based on its potential neurotrophic and pro-cognitive effects, but studies of its efficacy have yielded inconsistent results. OBJECTIVES: To …
BACKGROUND: Vascular dementia is a common disorder without definitive treatments. Cerebrolysin seems to be a promising intervention b …
Cerebrolysin: a review of its use in dementia.
Plosker GL, Gauthier S. Plosker GL, et al. Drugs Aging. 2009;26(11):893-915. doi: 10.2165/11203320-000000000-00000. Drugs Aging. 2009. PMID: 19848437 Review.
Cerebrolysin is a parenterally administered, porcine brain-derived peptide preparation that has pharmacodynamic properties similar to those of endogenous neurotrophic factors. ...Cerebrolysin was generally well tolerated in clinical trials, with dizziness (or vertig …
Cerebrolysin is a parenterally administered, porcine brain-derived peptide preparation that has pharmacodynamic properties similar to …
Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin.
Rejdak K, Sienkiewicz-Jarosz H, Bienkowski P, Alvarez A. Rejdak K, et al. Med Res Rev. 2023 Sep;43(5):1668-1700. doi: 10.1002/med.21960. Epub 2023 Apr 13. Med Res Rev. 2023. PMID: 37052231 Review.
Within the concept of NTFs in the treatment of these pathologies, we also review the neuropeptide preparation Cerebrolysin, which has been shown to resemble the activities of NTFs and to modulate the expression level of endogenous NTFs. Cerebrolysin has demonstrated …
Within the concept of NTFs in the treatment of these pathologies, we also review the neuropeptide preparation Cerebrolysin, which has …
Cerebrolysin for vascular dementia.
Cui S, Chen N, Yang M, Guo J, Zhou M, Zhu C, He L. Cui S, et al. Cochrane Database Syst Rev. 2019 Nov 11;2019(11):CD008900. doi: 10.1002/14651858.CD008900.pub3. Cochrane Database Syst Rev. 2019. PMID: 31710397 Free PMC article.
Secondary: to assess the adverse effects of Cerebrolysin and to assess the effect of Cerebrolysin on quality of life and caregiver burden. ...There have been no new studies of Cerebrolysin in vascular dementia since the last Cochrane Review. Cerebrolysin …
Secondary: to assess the adverse effects of Cerebrolysin and to assess the effect of Cerebrolysin on quality of life and careg …
582 results